Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Understanding Your LabsUnderstanding Your Labs
          
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


recent news on starting between 350 and 500
Nov 2, 2008

Hello - I am hoping you can comment on the recent news reports on the study by Mari Kitahata, a University of Washington AIDS researcher in Seattle.

It seems they are going to change the start meds at number from 200 to 350, or even higher than 350. Can you please comment for everyone?

Response from Dr. Holodniy

Not sure whether a change will occur in the guidelines, which currently state that anyone with a CD4 <200 or between 200-350 should start HIV treatment. There is currently a statement in the guidelines that says in those people with a CD4 count >350 treatment can be started based on the clinical history. The pendulum may swing toward a somewhat stronger statement regarding this based on some database reviews on outcomes at higher starting CD4 counts.



Previous
interleukin
Next
Taking Atripla on time

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement